Abstract
M. tuberculosis contains around a dozen potential Nudix hydrolases, and we are characterizing several of these enzymes as potential novel antibiotic targets. The diadenosine polyphosphatases (ApnAases) / mRNA decapping enzymes are a family of enzymes within the Nudix hydrolase superfamily. In M. tuberculosis there is a primary Nudix ApnAase and a secondary Nudix ApnAase. The diadenosine polyphosphatases from Legionella pneumophilia and Bartonella bacilliformis have been found to be important in each pathogen's ability to invade human host cells. We are interested in whether these enzymes act in the same way in M. tuberculosis. If they are found to be involved in invasiveness and thus in virulence, then these enzymes could be novel antibiotic targets. We have cloned, overexpressed, and purified the primary Nudix ApnAase from M. tuberculosis, and solved its structure with molecular replacement. The diffraction data had a resolution of 2.53 Å and a completeness of 99.92% resulting in a refined model with an R-free of 0.2835 and an R-work of 0.2293. We were able to crystallize the primary ApnAase with ATP in the Nudix hydrolase active site, which provided insight into ten residues that are potentially involved in hydrolysis. These residues could aid in the development of inhibitors against this enzyme, thus developing novel antibiotics against Mycobacterium tuberculosis.
Publication Date
8-16-2024
Document Type
Thesis
Student Type
Graduate
Degree Name
Chemistry (MS)
Department, Program, or Center
Chemistry and Materials Science, School of
College
College of Science
Advisor
Suzanne O'Handley
Advisor/Committee Member
Michael Gleghorn
Advisor/Committee Member
Emiliano Brini
Recommended Citation
Lynch, Aidan, "Structural Determination of the Nudix Hydrolase Rv2985, a Potential Antibiotic Target in Mycobacterium tuberculosis" (2024). Thesis. Rochester Institute of Technology. Accessed from
https://repository.rit.edu/theses/11874
Campus
RIT – Main Campus
Comments
This thesis has been embargoed. The full-text will be available on or around 8/27/2025.